TSTA3 Antibody

What is TSTA3 and what cellular functions does it perform?

TSTA3 (also known as FX, P35B, or SDR4E1) is a protein encoded by the GFUS gene that functions as GDP-L-fucose synthase. The human version consists of 321 amino acid residues with a molecular weight of approximately 35.9 kilodaltons. TSTA3 plays a critical role in fucosylation processes by catalyzing the conversion of GDP-4-keto-6-deoxymannose to GDP-L-fucose in the de novo pathway of fucose synthesis. This protein is notably expressed in tissues such as the testis, kidney, bronchus, breast, and adrenal gland. Its primary function involves metabolic processes related to protein glycosylation, particularly fucosylation, which affects various cellular functions including cell adhesion, signaling, and immune responses .

What are the key specifications to consider when selecting a TSTA3 antibody?

When selecting a TSTA3 antibody for research applications, researchers should consider:

• Antibody type (monoclonal vs. polyclonal): Monoclonal antibodies offer higher specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes and may provide stronger signals.

• Host species: Consider compatibility with other antibodies in multi-labeling experiments.

• Clonality: For monoclonal antibodies, knowing the clone (e.g., [C1C3]) can be important for reproducibility .

• Reactivity: Ensure the antibody recognizes the species of interest (human, mouse, rat, etc.) .

• Application validation: Verify the antibody has been validated for your specific application (WB, IHC, ELISA, etc.) .

• Epitope location: N-terminal, C-terminal, or internal region targeting can affect recognition of protein variants .

• Conjugation/tags: Available unconjugated or with various tags like biotin, Cy3, or DyLight488 .

• Citations in literature: Previously published research using the specific antibody can indicate reliability.

What are the optimal conditions for using TSTA3 antibodies in Western Blot applications?

For optimal Western Blot results with TSTA3 antibodies, researchers should consider the following protocol parameters:

Sample preparation:

• Extract proteins using RIPA buffer supplemented with protease inhibitors

• For detecting fucosylated TSTA3-modified proteins, consider specialized glycoprotein extraction protocols

• Typical protein loading: 20-50 μg total protein per lane

Gel electrophoresis:

• Use 10-12% SDS-PAGE gels (TSTA3 has a molecular weight of 35.9 kDa)

• Include positive controls from tissues known to express TSTA3 (e.g., testis, kidney)

Transfer conditions:

• PVDF membranes are generally preferred over nitrocellulose for TSTA3 detection

• Transfer at 100V for 60-90 minutes in standard transfer buffer

Blocking and antibody incubation:

• 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Typical dilutions range from 1:500 to 1:2000 depending on the specific antibody

• Incubate primary antibody overnight at 4°C with gentle rocking

Expected results:

• TSTA3 should appear as a band at approximately 36 kDa

• Validation can be performed using TSTA3 knockdown or overexpression samples, as demonstrated in ESCC studies

How can I optimize immunohistochemistry protocols for TSTA3 detection in tissue samples?

For optimal immunohistochemistry (IHC) detection of TSTA3 in tissue samples:

Tissue preparation:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Embed in paraffin and section at 4-5 μm thickness

• For tissue microarrays, ensure adequate representation of tumor and normal regions, as performed in ESCC studies

Antigen retrieval:

• Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 15-20 minutes

• Allow slides to cool to room temperature for 20 minutes

Primary antibody incubation:

• Dilute TSTA3 antibody (typically 1:50 to 1:200, optimize for each specific antibody)

• Incubate at 4°C overnight or 1-2 hours at room temperature in a humidified chamber

Detection and analysis:

• Use appropriate detection system (e.g., HRP-polymer or avidin-biotin complex)

• Develop with DAB substrate for 2-10 minutes (monitor under microscope)

• TSTA3 typically shows cytoplasmic staining pattern as observed in ESCC tissues

• For quantitative analysis, establish a standardized scoring system based on staining intensity and percentage of positive cells

Controls:

• Include positive controls (e.g., testis, kidney, or known TSTA3-expressing tumor tissues)

• Include negative controls (omit primary antibody)

• For specificity confirmation, consider using tissues with TSTA3 knockdown

What approaches can be used to validate the specificity of a TSTA3 antibody?

To validate the specificity of a TSTA3 antibody, researchers should employ multiple complementary approaches:

Genetic manipulation verification:

• TSTA3 knockdown using siRNA or shRNA in cell lines with high endogenous expression (as performed in KYSE180 and KYSE510 cells)

• TSTA3 overexpression in low-expressing cell lines (as demonstrated in KYSE150 and KYSE450 cells)

• Compare antibody signal between manipulated and control samples across applications

Recombinant protein and peptide blocking:

• Pre-incubate antibody with recombinant TSTA3 protein or immunizing peptide

• If specific, this should abolish or significantly reduce the signal

Application-specific validations:

• For Western blot: Confirm band size matches predicted molecular weight (35.9 kDa)

• For IHC/IF: Verify subcellular localization (cytoplasmic for TSTA3)

• Assess correlation between protein levels detected by the antibody and mRNA expression

Orthogonal method comparison:

• Compare protein expression with mRNA levels using RT-qPCR (as performed in ESCC studies)

• Correlate antibody signal with TSTA3 transcript abundance across tissue panels

A comprehensive validation should include documentation of these approaches and provide clear evidence of antibody specificity before proceeding with experimental applications.

How does TSTA3 regulation of fucosylation affect cancer metastasis mechanisms?

TSTA3's regulation of fucosylation significantly influences cancer metastasis through multiple mechanisms:

Altered fucosylation of key proteins:
Research in esophageal squamous cell carcinoma (ESCC) has revealed that TSTA3 overexpression increases both core fucosylation and terminal fucosylation of specific target proteins. Most notably, TSTA3 enhances fucosylation of LAMP2 (core fucosylation) and ERBB2 (terminal fucosylation), which together exert synergistic effects on promoting invasion and metastasis . These modified glycoproteins alter cellular adhesion properties, receptor signaling, and extracellular matrix interactions.

Experimental evidence:

• Transwell invasion assays demonstrate that TSTA3 overexpression markedly promotes ESCC cell invasion and migration without affecting proliferation .

• In vivo metastasis assays reveal that mice injected with TSTA3-overexpressing ESCC cells exhibit significantly increased lung metastatic nodules compared to control groups .

• Fucosylated protein enrichment experiments show that proteins enriched by UEA-I lectin (which binds α-1,2 fucosylated structures) from TSTA3-overexpressing cells promote invasion more strongly than those from control cells .

Reversibility of the phenotype:
Treatment with α-L-fucosidase to remove fucose residues or with peracetylated 2-F-Fuc (a fucosyltransferase activity inhibitor) reduces TSTA3 expression and fucosylation modification of target proteins, thereby inhibiting ESCC cell invasion . This demonstrates the direct link between TSTA3-mediated fucosylation and metastatic capability, suggesting potential therapeutic approaches targeting this pathway.

What methodological approaches are most effective for studying TSTA3-dependent fucosylation patterns?

Studying TSTA3-dependent fucosylation patterns requires a multi-faceted approach combining glycobiology techniques with modern proteomics:

Lectin-based analyses:

• Lectin blotting using fucose-specific lectins (e.g., LCA for core fucosylation, UEA-I for terminal α-1,2 fucosylation)

• Lectin immunofluorescence to visualize and quantify cellular fucosylation patterns, as demonstrated in ESCC cell lines

• Lectin affinity chromatography to enrich fucosylated proteins followed by mass spectrometry identification

Mass spectrometry-based glycoproteomics:

• N-glycoproteomics with enrichment strategies for fucosylated glycopeptides

• Intact glycopeptide analysis to determine fucosylation sites and structures

• Integration analysis of proteomics and glycoproteomics data, as performed in ESCC studies to normalize glycoprotein changes by protein abundance

Genetic manipulation models:

• TSTA3 overexpression systems in low-expressing cell lines

• TSTA3 knockdown using siRNA/shRNA in high-expressing cells

• Analysis of phenotypic and molecular changes in response to TSTA3 manipulation

Functional validation approaches:

• Fucosidase treatment to remove specific fucose linkages

• Fucosyltransferase inhibitors (e.g., peracetylated 2-F-Fuc) to block fucosylation

• Targeted mutagenesis of fucosylation sites on candidate proteins

In vivo models:

• Xenograft models with TSTA3-manipulated cancer cells

• PET/CT imaging to track metastasis formation, as demonstrated in ESCC mouse models

The combination of these approaches allows for comprehensive characterization of TSTA3-dependent fucosylation patterns and their functional consequences in disease states.

How do TSTA3 antibodies enable the identification of novel fucosylated protein targets?

TSTA3 antibodies serve as critical tools for identifying novel fucosylated protein targets through several sophisticated experimental approaches:

Comparative analysis between TSTA3-manipulated systems:

• TSTA3 antibodies confirm expression levels in cells with differential TSTA3 expression (overexpression vs. knockdown)

• Western blots using TSTA3 antibodies verify successful manipulation of TSTA3 expression levels

• Subsequent lectin-based enrichment of fucosylated proteins followed by mass spectrometry can identify differentially fucosylated proteins

Targeted validation of candidate proteins:

• After identifying potential fucosylated targets through N-glycoproteomics and lectin enrichment approaches, TSTA3 antibodies are essential for validation experiments

• Immunoprecipitation of candidate proteins followed by lectin blotting can confirm fucosylation

• In ESCC research, this approach identified LAMP2 and ERBB2 as important fucosylated targets of TSTA3

Dual-labeling immunofluorescence:

• TSTA3 antibodies combined with fucose-specific lectins in imaging studies

• Co-localization analysis can identify cellular compartments where TSTA3-mediated fucosylation occurs

• This approach was used in ESCC studies to demonstrate changes in fucosylation levels following TSTA3 manipulation

Functional rescue experiments:

• TSTA3 antibodies confirm expression levels in rescue experiments where wild-type TSTA3 is reintroduced to TSTA3-depleted cells

• This validation ensures that phenotypic changes and altered fucosylation patterns are specifically due to TSTA3 activity

By employing these methodologies, researchers can systematically identify novel fucosylated protein targets regulated by TSTA3, advancing our understanding of fucosylation-dependent cellular processes in both normal physiology and disease states.

How should researchers design experiments to study the relationship between TSTA3 expression and clinical outcomes?

Designing rigorous experiments to investigate the relationship between TSTA3 expression and clinical outcomes requires careful methodology across several domains:

Patient cohort selection and stratification:

• Ensure adequate sample size through power analysis (typically >100 patients for meaningful clinical correlations)

• Balance demographic factors (age, sex, ethnicity) between comparison groups

• Stratify patients by disease stage, treatment history, and molecular subtypes

• Include appropriate control tissues (adjacent normal, non-diseased samples from similar demographics)

• Document detailed clinical history and follow-up data (minimum 5-year follow-up recommended)

TSTA3 expression analysis:

• Employ multiple detection methods (IHC, qRT-PCR, Western blot)

• For IHC, use validated TSTA3 antibodies with demonstrated specificity

• Implement standardized scoring systems (H-score, Allred score, or digital image analysis)

• Ensure blinded assessment by at least two independent pathologists

Copy number and genetic analysis:

• Perform whole genome sequencing or targeted assays for TSTA3 locus

• Correlate copy number variation with expression levels

• In ESCC studies, this approach revealed a positive correlation between TSTA3 copy number and expression (Pearson correlation coefficient = 0.331)

Statistical analysis and outcome correlation:

Functional validation:

• Correlate TSTA3 expression with fucosylation patterns using lectin histochemistry

• Identify downstream fucosylated targets in patient samples

• Create predictive models incorporating TSTA3 with other biomarkers

This comprehensive approach would provide robust evidence regarding the clinical significance of TSTA3 expression in patient outcomes.

What are the critical quality control parameters for TSTA3 antibody-based experiments?

Ensuring experimental reliability with TSTA3 antibodies requires rigorous quality control measures across multiple parameters:

Antibody validation and characterization:

• Specificity verification through multiple methods (Western blot, immunoprecipitation, IHC with positive/negative controls)

• Epitope mapping to confirm binding region

• Cross-reactivity testing against related proteins

• Determination of optimal working concentration through titration experiments

Application-specific quality controls:

For Western blot:

• Molecular weight ladder to confirm expected band size (35.9 kDa for TSTA3)

• Positive control samples (tissues/cells known to express TSTA3)

• Negative control samples (TSTA3 knockdown/knockout)

• Loading controls (GAPDH, β-actin, total protein staining)

• As demonstrated in ESCC studies, TSTA3 antibodies should detect bands at the appropriate molecular weight that increase or decrease in accordance with genetic manipulation

For Immunohistochemistry:

• Positive tissue controls on each slide (testis, kidney, or known TSTA3-positive tumors)

• Negative control sections (primary antibody omitted)

• Internal controls within each tissue section

• TSTA3 should show the expected cytoplasmic localization pattern as observed in ESCC tissues

Documentation and reporting:

• Detailed antibody information (catalog number, lot number, source)

• Complete experimental conditions (concentration, incubation time/temperature)

• Representative images of all controls

• Quantification methods and statistical analysis parameters

How can researchers distinguish between direct and indirect effects of TSTA3 on protein fucosylation?

Distinguishing between direct and indirect effects of TSTA3 on protein fucosylation requires sophisticated experimental approaches:

Enzymatic activity assays:

• In vitro GDP-fucose synthase activity assays using purified recombinant TSTA3

• Measurement of conversion rates of GDP-4-keto-6-deoxymannose to GDP-L-fucose

• Quantification of GDP-fucose production in cell lysates with varying TSTA3 expression levels

Rescue experiments:

• TSTA3 knockdown followed by supplementation with exogenous GDP-fucose

• If fucosylation is restored by GDP-fucose addition, effects are likely direct

• Expression of catalytically inactive TSTA3 mutants as negative controls

Protein-specific fucosylation analysis:

• Site-specific glycopeptide analysis by mass spectrometry

• Identification of fucosylation sites on candidate proteins

• In ESCC studies, this approach identified LAMP2 and ERBB2 as targets of TSTA3-mediated fucosylation

Inhibitor studies:

• Use of specific fucosyltransferase inhibitors to block downstream effects

• Application of peracetylated 2-F-Fuc as shown in ESCC studies

• Selective inhibition of signaling pathways potentially linking TSTA3 to fucosylation

Example experimental workflow to distinguish direct vs. indirect effects:

• Generate TSTA3 knockout cells using CRISPR-Cas9

• Perform global glycomic analysis to identify all altered fucosylated structures

• Conduct metabolic labeling with azido-fucose in short time intervals

• Enrich and identify labeled glycoproteins at each time point

• Classify glycoproteins as early-responding (potential direct targets) vs. late-responding

• Validate direct targets by supplementing with exogenous GDP-fucose

By systematically applying these approaches, researchers can effectively differentiate between glycoproteins directly affected by TSTA3-generated GDP-fucose and those modified through secondary mechanisms or regulatory cascades.

How should conflicting results in TSTA3 expression studies be reconciled and explained?

Conflicting results in TSTA3 expression studies can be systematically approached through:

Methodological reconciliation:
When interpreting contradictory findings about TSTA3 expression, researchers should first consider methodological differences. As noted in ESCC studies, "the increase of TSTA3 expression level in tumor samples was not obvious in comparison with non-tumor samples" in RNA sequencing data, while immunohistochemistry showed significant upregulation in protein levels . These discrepancies highlight potential disparities between mRNA and protein expression, suggesting post-transcriptional regulation. Researchers should:

• Compare detection methods (RNA-seq, qRT-PCR, Western blot, IHC) and their sensitivity

• Examine antibody clones and epitopes used across studies

• Consider sample preparation differences (fresh-frozen vs. FFPE tissues)

• Evaluate quantification methods (relative vs. absolute quantification)

Biological heterogeneity factors:

• Tissue-specific expression patterns (TSTA3 is differentially expressed across tissues)

• Tumor heterogeneity (sampling from different regions may yield different results)

• Disease stage variations (early vs. advanced disease)

• In ESCC studies, TSTA3 expression showed trends toward correlation with clinical stage and lymphatic metastasis, though not reaching statistical significance in mRNA analysis

Reconciliation strategies:

• Multimodal validation:

  • Apply multiple detection methods to the same sample set

  • Correlate RNA and protein expression in matched samples

  • Use single-cell approaches to resolve heterogeneity issues

• Contextual analysis:

  • Stratify results by clearly defined clinical parameters

  • Consider molecular subtypes of the disease

  • Analyze expression in context of pathway activation states

For TSTA3 in ESCC, the apparent discrepancy between mRNA and protein expression could be addressed by examining post-transcriptional regulation mechanisms and analyzing protein stability and turnover rates.

What statistical approaches are most appropriate for analyzing TSTA3 antibody-generated data in cancer research?

Analyzing TSTA3 antibody-generated data in cancer research requires tailored statistical approaches depending on the experimental design and data type:

Data preprocessing and quality control:

• Outlier detection and handling (Grubbs' test, Dixon's Q test)

• Normality testing (Shapiro-Wilk, Kolmogorov-Smirnov)

• Variance homogeneity assessment (Levene's test, Bartlett's test)

• Technical variation normalization (housekeeping proteins, total protein normalization)

Statistical analysis by data type:

• Continuous expression data (Western blot densitometry, digital IHC quantification):

  • Parametric tests: t-test (paired/unpaired), ANOVA with post-hoc tests (Tukey, Bonferroni)

  • Non-parametric alternatives: Mann-Whitney U, Wilcoxon signed-rank, Kruskal-Wallis

  • In ESCC studies, paired t-tests were used to compare TSTA3 expression between tumor and normal tissues

• Semi-quantitative IHC scoring:

  • Weighted kappa statistics for inter-observer agreement

  • Ordinal regression models for correlations with clinical parameters

  • Chi-square or Fisher's exact test for categorical comparisons

• Survival analysis:

  • Optimal cutpoint determination using ROC curve analysis, as performed in ESCC studies

  • Kaplan-Meier method with log-rank test for univariate analysis

  • Cox proportional hazards models for multivariate analysis

  • In ESCC research, this approach revealed that patients with high TSTA3 expression had shorter survival time than those with low expression

• Integration with genomic data:

  • Correlation between protein expression and copy number (Pearson/Spearman)

  • In ESCC studies, this approach showed a positive correlation between TSTA3 copy number and expression (r = 0.331)

Reporting standards:

• Clear specification of statistical tests used

• Exact p-values rather than thresholds (p < 0.05)

• Effect sizes with confidence intervals

• Transparency about excluded samples and missing data

How can researchers integrate TSTA3 functional data with broader glycoproteomic datasets?

Integrating TSTA3 functional data with broader glycoproteomic datasets requires sophisticated computational and experimental approaches:

Experimental design for integrative analysis:

• Matched sample collection for parallel analyses (same samples for TSTA3 functional studies and glycoproteomics)

• Perturbation experiments with TSTA3 manipulation (overexpression, knockdown, inhibition)

• Inclusion of appropriate controls for each data layer

Glycoproteomics data preprocessing:

• Quality filtering of glycopeptide identifications (FDR < 1%)

• Normalization of glycopeptide abundances

• Site-specific glycosylation quantification

• Glycan structure assignment and classification

• Fucosylation-specific feature extraction

Integration strategies:

• Correlation-based approaches:

  • Correlation of TSTA3 expression/activity with fucosylation levels across glycoproteins

  • Identification of glycoproteins whose fucosylation most strongly correlates with TSTA3

  • In ESCC studies, this approach helped identify key fucosylated targets modified by TSTA3

• Network-based integration:

  • Construction of fucosylation-centered protein-glycan networks

  • Positioning of TSTA3 within the network context

  • Identification of network modules associated with TSTA3 function

• Pathway-centric integration:

  • Enrichment analysis of fucosylated proteins in biological pathways

  • Identification of pathways differentially affected by TSTA3 manipulation

  • Integration with transcriptional response to TSTA3 perturbation

Case study application to ESCC research:
In ESCC studies, integration approaches included:

• N-glycoproteomics combined with proteomics to normalize for protein abundance changes

• Lectin enrichment coupled with mass spectrometry for fucosylated protein identification

• Functional validation of key targets (LAMP2, ERBB2) identified through integrative analysis

• Correlation of fucosylation patterns with invasive phenotypes

A comprehensive integration workflow might include:

• Quantitative profiling of the glycoproteome in TSTA3-manipulated systems

• Parallel measurement of TSTA3 enzymatic activity and GDP-fucose levels

• Identification of differentially fucosylated proteins

• Network construction connecting TSTA3 to fucosylation machinery and substrates

• Pathway enrichment analysis of affected glycoproteins

• Functional validation of key targets through site-directed mutagenesis

This integrative approach provides a comprehensive understanding of how TSTA3 functions within the broader context of cellular glycosylation networks and identifies critical nodes that may serve as biomarkers or therapeutic targets.